Osteogenesis Imperfecta Treatment Market Is Witnessing Robust Growth As Mereo Biopharma Received The U.S. FDA’s Grant For Rare Pediatric Disease Designation To Setrusumab For The Treatment Of Osteogenesis Imperfecta
Osteogenesis imperfecta is a type of malformation that occurs when the beginnings of bone formation are hindered or deficient. The word "imperfect" is an understatement when it comes to this disorder because it is difficult to diagnose and can affect any part of the body. This disorder starts in early childhood and may continue into adulthood. For the treatment of any disease, research and development play a crucial role. Many companies in the field of biotechnology are engaged in clinical trials and collaborative research for osteogenesis imperfecta treatment. Recently, in December 2020, Mereo BioPharma Group entered into a US$ 50 million partnership with Ultragenyx for a rare bone disease drug with licensing deal focusing on setrusumab in osteogenesis imperfecta (OI). Such research activities can accelerate growth of the osteogenesis imperfect treatment market.
The prevalence of osteogenesis
imperfecta has increased in various countries. As a result of this, the demand
for proper treatment has increased significantly. Although it is a rare
disease, government authorities are required to keep track of any surge in a
number of cases. As per the National Organization for Rare Diseases (NORD), OI
type I is expected to occur in one in 30,000 live births, while OI type II is
projected to occur in one in 60,000 live births. As per the same source, around
20,000 to 50,000 individuals in the U.S. have OI. Such high prevalence has
increased the demand for adequate treatment options, which could prompt growth
of the osteogenesis imperfecta treatment market.
Recently, in September 2020, Mereo
BioPharma Group received the U.S. Food and Drug Administration (FDA) granted
rare pediatric disease designation to setrusumab for the treatment of
osteogenesis imperfecta.
When it comes to regions, developed
regions such as Europe are witnessing high demand for osteogenesis imperfecta
treatment. The research on OI treatment has witnessed massive acceleration over
the years with various key biotechnology companies collaborating to develop a
potential treatment for this disease. In May 2019, Mereo BioPharma Group
presented 6-month data from its phase II-B clinical study in adult patients
with Type III, IV, or I osteogenesis imperfecta treated with setursumab
(BPS-804).
Manual treatment options include the
use of lasers, X-rays, scalpels, and surgical tools. These treatment options
are effective for some but they are costly and may cause other conditions such
as infection. Many of these treatments may not even be effective as a treatment
for Osteogenesis imperfecta itself. The reason for this is due to this disorder
stems from several different root causes that are often not treated properly by
these conventional treatments. Regardless, there is a lack of skilled personnel
for the treatment of such a rare disorder. Besides, there is no effective
treatment available that can cure OI completely, which could inhibit growth of
the osteogenesis imperfecta treatment market in the near future.
Comments
Post a Comment